ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026
miR-7847-3p Serves as a Prognostic Biomarker and Suppresses Colorectal Cancer Progression.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsMiR-7847-3p is aberrantly expressed in multiple cancer types; however, its biological function and molecular mech anism in colorectal cancer (CRC) remain unclear. This investigation aims to explore the function of miR-7847-3p in CRC development and its potential regulatory mechanisms. MATERIALS AND
methodsTumor tissues and paracancerous normal tissues from 122 CRC patients were collected and miR-7847-3p expression was detected by quantitative reverse transcription polymerase chain reaction. The predictive capacity of miR-7847-3p was evaluated through Kaplan-Meier survival analysis and subsequently validated via multivariable Cox proportional hazards modeling. The effects of miR-7847-3p on HCT116 and SW480 cells were evaluated through Cell Counting Kit-8 and Transwell assays. The miR 7847-3p target genes were predicted using TargetScan, miRDB, and miRWalk. Dual-luciferase reporter assay confirmed the regulatory relationship between miR-7847-3p and AP1S1.
resultsThe miR-7847-3p expression was downregulated in CRC tumor tissues and CRC cell lines (HCT116 and SW480 cells). Reduced expression levels of miR-7847-3p are associated with advanced lymph node metastasis, Tumor-node-metastasis stage, and poorer 5-year survival. The miR-7847-3p downregulation signature proved to be a standalone prognostic indicator in CRC. Functional studies indicated that overexpression of miR-7847-3p inhibited CRC cell proliferation, migration, and invasion, while its knockdown promoted these malignant behaviors. Bioinformatics predictions and dual luciferase reporter assay confirmed AP1S1 is a downstream gene of miR-7847-3p.
conclusionMiR-7847-3p is downregulated in CRC and is associated with poor prognosis. Its overexpression can inhibit the prolifera tion, migration, and invasion of CRC cells, possibly by targeting AP1S1, suggesting the dual potential of miR-7847-3p as a prognostic biomarker and therapeutic target. Cite this article as: Chen H, Wang Y, Lu M. MiR-7847-3p serves as a prognostic biomarker and suppresses colorectal cancerprogression. Turk J Gastroenterol. 2026;37(3):292-300.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.